<Research>CCBI: Healthcare & Biotech Sectors Highly Valued, but Sector Drivers Remain Strong
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Source: aastocks
Market Performance: The biotech sector in Hong Kong saw a significant surge in share prices, increasing by 137% YTD, but recently faced a correction due to disappointing drug sales from companies like ZAI LAB and HUTCHMED, alongside concerns over potential US tariffs on Chinese pharmaceuticals.
Broker Recommendations: CCBI has identified INNOVENT BIO as a top pick, expecting its losses to narrow and projecting adjusted profits of RMB5 million, leading to an increase in its target price from $100 to $110 with an Outperform rating.
Analyst Views on 00013
Wall Street analysts forecast 00013 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00013 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.420
Low
Averages
High
Current: 23.420
Low
Averages
High
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
